Assessment of Hematopoietic Recovery Following Chemotherapy for Non-Hodgkin's Lymphoma

University of Oklahoma35 enrolled

Overview

A study to determine the accuracy of FLT-PET in quantifying tumor cell proliferation at the initial staging of patients with Non-Hodgkin's Lymphoma in comparison wit the "gold standard" FDG-PET.

The first primary objective reflects a necessary and preliminary requirement: to reproduce published results and validate the use of FLT-PET. In this study, 35 patients will be selected to undergoing imaging with both FLT and FDG PET.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Non-Hodgkin's Lymphoma

Interventions

FLT-PET scanPROCEDURE

imaging scan

FDG-PET scanPROCEDURE

imaging scan

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older * Women must not be pregnant or breast feeding * Histologic diagnosis of non-Hodgkin's lymphoma (any stage) * Must undergo treatment with chemotherapy and/or radiotherapy Exclusion Criteria: * May not have received previous therapy with radiopharmaceuticals * May not have received prior therapy with cytotoxic chemotherapy and/or monoclonal antibodies

Locations (1)

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, United States

Outcomes

Primary Outcomes

Staging and ReStaging scans

Time frame: after hematopoetic recovery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.